chemotherapi
hdct
follow
autolog
haematopoiet
stem
cell
transplant
hsct
wide
use
treatment
advanc
refractori
paediatr
solid
mani
chemotherapeut
agent
alkyl
agent
anthracyclin
vinca
alkaloid
produc
steep
curv
differ
tumour
cell
hdct
dose
chemotherapeut
agent
escal
least
treatment
may
produc
bone
marrow
failur
patient
receiv
autolog
hsct
recov
bone
marrow
function
howev
concern
still
exist
regard
toxic
effect
hdct
organ
toxic
effect
lung
hsct
common
contribut
significantli
patient
morbid
prophylaxi
treatment
infecti
complic
continu
advanc
noninfecti
pulmonari
complic
becom
toxic
lung
hdct
autolog
hsct
report
implic
chemotherapeut
agent
includ
melphalan
carmustin
bcnu
noninfecti
interstiti
lung
diseas
ild
one
recogn
lung
injuri
occur
adult
patient
allogen
even
though
mani
chemotherapeut
agent
bleomycin
busulfan
chlorambucil
cyclophosphamid
methotrex
mitomycin
nitrosourea
known
caus
ild
studi
investig
noninfecti
ild
autolog
hsct
especi
paediatr
therefor
intend
determin
incid
noninfecti
ild
clinic
characterist
patient
risk
factor
associ
noninfecti
ild
hdct
autolog
hsct
paediatr
patient
retrospect
cohort
studi
conduct
singl
tertiari
institut
medic
record
consecut
patient
year
age
solid
tumour
treat
hdct
chemotherapi
autolog
hsct
april
septemb
review
patient
undergon
addit
allogen
hsct
autolog
hsct
exclud
fig
clinic
research
protocol
approv
institut
review
board
samsung
medic
centr
irb
patient
receiv
hdct
accord
underli
patholog
risk
group
includ
condit
regimen
carboplatin
etoposid
melphalan
cem
first
hdct
carboplatin
etoposid
cyclophosphamid
ceci
first
hdct
carboplatin
thiotepa
melphalan
ctm
second
hdct
thiotepa
melphalan
tm
second
hdct
neuroblastoma
patient
brain
tumour
patient
carboplatin
thiotepa
etoposid
cte
first
hdct
cyclophosphamid
melphalan
cym
second
hdct
use
cem
regimen
consist
carboplatin
day
etoposid
day
melphalan
day
day
ceci
regimen
includ
carboplatin
day
etoposid
day
cyclophosphamid
day
sulfon
sodium
carboplatin
day
thiotepa
day
melphalan
day
make
ctm
regimen
tm
regimen
includ
thiotepa
day
melphalan
without
mibg
treatment
therapeut
mibg
mcikg
administ
first
second
hdct
session
cte
regimen
entail
carboplatin
day
thiotepa
day
etoposid
day
final
cym
regimen
consist
cyclophosphamid
day
melphalan
day
dosag
hdct
regimen
similar
dosag
chemotherapeut
agent
state
earlier
except
modif
tbi
deliv
fraction
dose
cgyfract
fraction
stem
cell
collect
peripher
blood
recoveri
phase
chemotherapi
steadi
state
alon
noninfecti
ild
defin
follow
present
clinic
symptom
sign
cough
dyspnea
desatur
ii
diffus
parenchym
infiltr
chest
comput
tomographi
ct
iii
lesion
caus
pneumonia
diagnos
clinic
resolut
symptom
antimicrobi
support
treatment
andor
detect
pathogen
microorgan
respiratori
secret
lung
biopsi
tissu
iv
lesion
caus
pulmonari
congest
effus
v
evid
metastat
lung
lesion
respiratori
secret
test
identifi
infecti
pathogen
respiratori
sampl
includ
endotrach
aspir
bronchoalveolar
lavag
bal
nasopharyng
aspir
viru
cultur
perform
detect
adenoviru
respiratori
syncyti
viru
influenza
viru
parainfluenza
viru
whilst
multiplex
polymeras
chain
reaction
use
detect
adenoviru
respiratori
syncyti
viru
influenza
viru
parainfluenza
coronaviru
rhinoviru
gram
stain
cultur
also
perform
tracheal
bronchial
secret
fungi
cultur
separ
media
use
tracheal
suction
bal
fluid
galactomannan
immunosorb
assay
aspergillu
speci
test
serum
bal
fluid
mycobacterium
bacillu
stain
cultur
dna
polymeras
chain
reaction
perform
mycoplasma
pneumonia
studi
antibodi
titer
blood
dna
detect
respiratori
secret
pneumocysti
jirovecii
evalu
fluoresc
stain
secret
smear
lung
biopsi
conduct
use
thoracoscop
surgeri
acut
subacut
stage
symptom
patient
could
toler
oper
biopsi
specimen
test
adenoviru
pneumocysti
jirovecci
cytomegaloviru
immunohistochemistri
paramet
analys
potenti
risk
factor
noninfecti
ild
includ
age
hdct
gender
underli
tumour
diagnosi
use
chemotherapi
agent
cisplatin
etoposid
cyclophosphamid
carboplatin
vincristin
ifosfamid
doxorubicin
methotrex
actinomycin
bleomycin
use
hdct
agent
carboplatin
thiotepa
melphalan
cyclophosphamid
etoposid
busulfan
ifosfamid
mibg
treatment
usag
number
hdct
treatment
total
bodi
irradi
thorac
field
radiat
therapi
associ
develop
noninfecti
ild
potenti
risk
factor
assess
use
univari
multivari
cox
proport
hazard
regress
model
stepwis
select
test
consid
statist
signific
sa
program
ver
sa
institut
cari
nc
usa
use
statist
analys
studi
includ
total
patient
one
hundr
six
patient
symptom
radiolog
suggest
ild
patient
diagnos
clinic
pneumonia
fig
patient
pathogen
microorgan
detect
includ
respiratori
syncyti
viru
influenza
viru
parainfluenza
viru
bacteria
adenoviru
mycoplasma
pneumonia
coronaviru
rhinoviru
fungu
pneumocysti
patient
diagnos
pneumonia
accord
clinic
cours
diseas
median
age
particip
year
interquartil
rang
iqr
common
primari
diagnosi
neuroblastoma
follow
medulloblastoma
number
hdct
autolog
hsct
treatment
patient
patient
common
hdct
regimen
cyclophosphamid
melphalan
follow
carboplatin
etoposid
cyclophosphamid
carboplatin
thiotepa
etoposid
patient
receiv
total
bodi
irradi
thorac
area
radiat
therapi
mibg
treatment
therapi
tabl
eight
patient
diagnos
noninfecti
ild
fig
histori
seriou
respiratori
infect
diagnos
ild
median
age
eight
patient
year
rang
median
durat
symptom
onset
hdct
autolog
hsct
month
rang
patient
receiv
system
steroid
part
treatment
ild
diagnosi
five
patient
subject
administ
methylprednisolon
puls
therapi
day
six
eight
die
studi
period
ct
find
subpleur
thicken
consolid
interstiti
thicken
ground
glass
opac
lung
biopsi
show
interstiti
fibrosi
andor
thicken
inflammatori
cell
infiltr
pleural
thicken
eight
patient
receiv
cyclophosphamid
condit
regimen
autolog
hsct
tabl
base
upon
univari
analysi
risk
factor
noninfecti
ild
femal
gender
p
use
cyclophosphamid
hdct
regimen
p
mibg
treatment
p
tabl
usual
dose
chemotherapi
includ
cyclophosphamid
p
cisplatin
p
carboplatin
p
etoposid
p
vincristin
p
ifosfamid
p
doxorubicin
p
methotrex
p
actinomycin
p
bleomycin
p
significantli
associ
develop
noninfecti
ild
multivari
analysi
reveal
cyclophosphamid
p
hazard
rate
ci
male
gender
p
hazard
rate
ci
associ
noninfecti
ild
tabl
studi
incid
noninfecti
ild
follow
hdct
autolog
hsct
paediatr
solid
tumour
patient
cyclophosphamid
hdct
regimen
femal
gender
signific
predictor
develop
noninfecti
ild
patient
show
delay
onset
symptom
six
eight
ild
patient
die
studi
period
even
though
patient
administ
steroid
treatment
ild
incid
noninfecti
ild
follow
autolog
hsct
well
known
adult
studi
incid
noninfecti
ild
follow
allogen
bone
marrow
transplant
paediatr
autolog
hsct
studi
two
patient
show
abnorm
chest
respiratori
symptom
restrict
pulmonari
function
test
infecti
caus
incid
noninfecti
ild
autolog
hsct
may
differ
differ
studi
group
depend
patient
age
underli
diseas
treatment
clinic
featur
patient
fit
well
previous
report
syndrom
noninfecti
pulmonari
complic
hsct
idiopath
pneumonia
syndrom
ip
one
common
pulmonari
complic
american
thorac
societi
defin
ip
follow
widespread
alveolar
injuri
ii
absenc
infect
iii
absenc
cardiac
renal
iatrogen
similar
definit
noninfecti
ild
except
limit
injuri
site
alveoli
instead
entir
lung
parenchyma
mortal
ip
patient
similar
pulmonari
complic
follow
predict
timelin
onset
time
median
day
rang
day
hsct
one
major
differ
patient
present
symptom
day
six
patient
develop
symptom
delay
pulmonari
toxic
syndrom
anoth
form
pulmonari
injuri
occur
hdct
autolog
hsct
breast
cancer
patient
delay
pulmonari
toxic
syndrom
develop
symptom
mean
onset
week
hdct
contain
cyclophosphamid
cisplatin
unlik
patient
show
good
respons
steroid
treatment
good
prognosi
mani
drug
known
caus
ild
ild
attribut
incid
ild
well
known
incid
densiti
per
million
report
studi
period
time
trend
incid
statist
cyclophosphamid
known
caus
ild
clinic
patholog
pattern
ild
subacut
interstiti
pneumonia
pulmonari
fibrosi
acut
respiratori
distress
syndrom
organ
ild
includ
produc
cyclophosphamid
may
develop
administr
medic
also
present
sever
year
pulmonari
fibrosi
identifi
two
children
treat
report
year
later
children
receiv
diagnosi
ild
made
tempor
elig
exclus
caus
difficult
diagnos
patient
develop
symptom
finish
medic
studi
cyclophosphamid
associ
increas
risk
ild
rais
high
suspicion
cyclophosphamid
caus
role
ild
deplet
reduc
glutathion
impair
antioxid
defenc
might
suggest
possibl
accord
univari
analysi
conduct
studi
mibg
treatment
femal
gender
ild
risk
factor
mibg
share
uptak
releas
mechan
norepinephrin
use
detect
neuroendocrin
tumour
target
radiotherapi
advanc
also
taken
lung
transport
mechan
mibg
scintigraphi
use
assess
pulmonari
endotheli
cell
mibg
group
transient
interstiti
pneumonia
fatal
pneumonia
report
risk
pulmonari
complic
warrant
investig
even
though
gender
risk
factor
studi
specif
mechan
trend
known
differ
pulmonari
fibrosi
report
anim
male
gender
also
determin
risk
factor
ild
lung
cancer
patient
receiv
gefitinib
gender
effect
develop
ild
autolog
hsct
need
studi
total
bodi
irradi
tbi
cgi
among
patient
older
year
also
known
produc
high
risk
howev
tbi
associ
ild
studi
may
due
young
age
patient
lower
dose
tbi
cgyfract
fraction
use
bleomycin
methotrex
drug
known
caus
use
convent
chemotherapi
dose
studi
group
signific
associ
noninfecti
ild
larg
studi
number
autolog
hsct
n
patient
allow
us
analys
risk
factor
associ
noninfecti
ild
autolog
hsct
previous
anecdot
report
investig
regard
one
individu
therapeut
agent
individu
diseas
case
long
period
median
year
allow
detect
noninfecti
ild
limit
studi
could
obtain
pulmonari
function
test
screen
test
patient
young
perform
addit
approxim
ild
patient
may
present
abnorm
chest
therefor
ild
patient
minim
symptom
normal
chest
may
detect
use
studi
definit
incid
could
higher
reason
caution
use
interpret
neg
result
suspect
risk
factor
popul
conclus
studi
present
incid
noninfecti
ild
autolog
hsct
paediatr
solid
tumour
patient
femal
gender
cyclophosphamid
treatment
might
risk
factor
noninfecti
ild
studi
larger
number
noninfecti
ild
patient
suggest
